- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04463121
Preload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06) (CS-06)
Pressure-Volume (PV) Measurements for Evaluating the Changes in the Ventricular Preload and Autonomic Nervous System Using BackBeat Medical Cardiac Neuromodulation Therapy (CNT) Signals in an Acute Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects indicated for a dual chamber pacemaker implant or replacement who are not 100% dependent on right ventricular pacing may be eligible to participate in the study.
This investigation will evaluate the effect of RV pacing lead position on cardiac function and the modulation of the autonomic nervous system using Cardiac Neuromodulation Therapy (CNT) pacing signals at different positions of the RV pacing lead.
A standard conductance catheter will be introduced through the femoral artery and advanced into the left ventricle to measure cardiac volumes and pressure.
Arterial blood pressure will be measured from the other femoral artery with an additional sheath.
The Moderato® IPG will be used to generate Cardiac Neuromodulation Therapy (CNT) signals and deliver them to the patient through the cable and leads. A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead. Ventricular pressure and volume readings from the conductance catheter and arterial pressure readings will be recorded and analyzed to assess the effect of CNT signals on cardiac function, sympathetic activity and blood pressure.
The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yuval Mika, PhD
- Phone Number: +18569123155
- Email: ymika@orchestrabiomed.com
Study Contact Backup
- Name: Norbert Rosenthal
- Phone Number: +491792482543
- Email: nrosenthal@orchestrabiomed.com
Study Locations
-
-
-
Praha, Czechia, 15030
- Recruiting
- Na Homolce Hospital
-
Contact:
- Petr Neuzil, MD, PhD
- Phone Number: +420 257272211
- Email: Peter.Neuzil@homolka.cz
-
Contact:
- Libor Dujka, MD
- Phone Number: +420731486352
- Email: libor.dujka@homolka.cz
-
Principal Investigator:
- Petr Neuzil, MD, PhD
-
Sub-Investigator:
- Filip Malek, MD, PhD
-
Sub-Investigator:
- Jan Petru, MD
-
Sub-Investigator:
- Milan Chovanec, MD
-
Sub-Investigator:
- Libor Dujka, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject requires implantation or replacement of a dual chamber pacemaker or requires an upgrade from a single chamber to a dual chamber pacemaker
- Subject has known Hypertension
- Subject is willing and able to comply with the study and procedures.
Exclusion Criteria:
- Subject has symptoms of heart failure, NYHA Class II or greater
- Subject has significant (>2+) mitral regurgitation, aortic regurgitation or aortic stenosis.
- Subject has permanent atrial fibrillation
- Subject has atrial fibrillation on the day of the study.
- Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy or interventricular septal thickness ≥15 mm
- Subject is on dialysis
- Subject has a history of prior neurological events (stroke or TIA) within the past year or a neurological event (stroke or TIA) at any prior time that has resulted in residual neurologic deficit.
- Subject has a history of autonomic dysfunction
- Women who are pregnant or breast-feeding
- Subject cannot or is unwilling to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acute CNT pacing signals testing
Acute study procedure will be carried out prior to a pacemaker implantation or replacement: pacemaker Right Atrial (RA) and Right Ventricular (RV) leads will be positioned according to standard procedure for pacemaker implant and connected to a Moderato® System IPG, via a single use, sterile Pacing System Analyzer (PSA) cable. The Moderato IPG will deliver CNT signals. Furthermore, a standard conductance catheter in the left ventricle will measure cardiac volumes and pressure. Arterial blood pressure will be obtained as well. A range of CNT signal parameters will be used to assess the effect on sympathetic activity at different positions of the RV pacing lead while ventricular pressure and volume and arteial pressure signals will be assesed for cardiac function, sympathetic activity and blood pressure. The effects of CNT signal over a range of parameter settings will be studied for the different RV lead positions. |
Assesment of cardiac function and sympatheric activity will be obtained simultaneously
Simultaneous recording of the Pressure, Volume measurements and ECG signals will be done for constant monitoring of intra-ventricular pressure and volume.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of the Moderato CNT pacing signals on cardiac function
Time Frame: approximately one hour
|
Left ventricular pressure (mmHg) and Volume (ml) will be obtained by a multisensor catheter which provides real-time, beat-to-beat intra-ventricular measurement of cardiac function and performance.
Data will be used to generate Pressure-Volume Loops, an aknowledged way to describe hemodynamic changes.
CNT signals (alternating short and long atrioventicular sequences 40-150 ms) will be delivered at the same by right ventricular pacemaker leads temporarely connected to the Moderato device.
|
approximately one hour
|
Effects of CNT pacing signals on blood pressure
Time Frame: aproximately onr hour
|
Blood pressure (mmHg) will be obtained in parallel with a Millar catheter from the femoral artery througout the study.
|
aproximately onr hour
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Yang B, Wang Y, Zhang F, Ju W, Chen H, Mika Y, Aviv R, Evans SJ, Burkhoff D, Wang J, Chen M. Rationale and evidence for the development of a durable device-based cardiac neuromodulation therapy for hypertension. J Am Soc Hypertens. 2018 May;12(5):381-391. doi: 10.1016/j.jash.2018.03.004. Epub 2018 Mar 21.
- Neuzil P, Merkely B, Erglis A, Marinskis G, de Groot JR, Schmidinger H, Rodriguez Venegas M, Voskuil M, Sturmberger T, Petru J, Jongejan N, Aichinger J, Kamzola G, Aidietis A, Geller L, Mraz T, Osztheimer I, Mika Y, Evans S, Burkhoff D, Kuck KH; BackBeat Study Investigators. Pacemaker-Mediated Programmable Hypertension Control Therapy. J Am Heart Assoc. 2017 Dec 23;6(12):e006974. doi: 10.1161/JAHA.117.006974.
- de Roest GJ, Allaart CP, Kleijn SA, Delnoy PP, Wu L, Hendriks ML, Bronzwaer JG, van Rossum AC, de Cock CC. Prediction of long-term outcome of cardiac resynchronization therapy by acute pressure-volume loop measurements. Eur J Heart Fail. 2013 Mar;15(3):299-307. doi: 10.1093/eurjhf/hfs190. Epub 2012 Nov 25.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBM MOD PV CS-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bradycardia
-
Augusta UniversityCompletedFetal BradycardiaUnited States
-
University of Maryland, BaltimoreCompleted
-
Chun Chieh WangEnrolling by invitation
-
University of Sao Paulo General HospitalCompletedFetal Bradycardia | Hypertonic Uterine | CatecholaminesBrazil
-
University of ExeterRoyal Devon and Exeter NHS Foundation TrustCompletedSVT | Vagal BradycardiaUnited Kingdom
-
Abbott Medical DevicesCompletedStandard Bradycardia Pacing IndicationFrance, Germany, Italy, Japan
-
Medical University of GdanskCompletedBradycardia During Pulling of EyeballPoland
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
South Western Ambulance Service NHS Foundation...Royal Devon and Exeter NHS Foundation Trust; Academic Health Science CentresCompletedEmergencies | SVT | Vagal BradycardiaUnited Kingdom
-
Unyime ItukRecruitingFetal Heart Rate or Rhythm Abnormality Affecting Fetus | Fetal Bradycardia Complicating Labor and Delivery | Fetal Bradycardia During LaborUnited States
Clinical Trials on Moderato IPG's CNT pacing signals
-
BackBeat Medical IncRecruitingHypertension,Essential | Systolic HypertensionPoland, Czechia, Hungary
-
Parc de Salut MarRecruitingPacemaker DDD | Conduction DisorderSpain